Clinical Benefits of an Adherence Monitoring Program in the Management of Secondary Hyperparathyroidism with Cinacalcet: Results of a Prospective Randomized Controlled Study

Background/Aims. One of the causes of uncontrolled secondary hyperparathyroidism (sHPT) is patient's poor drug adherence. We evaluated the clinical benefits of an integrated care approach on the control of sHPT by cinacalcet. Methods. Prospective, randomized, controlled, multicenter, open-label study. Fifty hemodialysis patients on a stable dose of cinacalcet were randomized to an integrated care approach (IC) or usual care approach (UC). In the IC group, cinacalcet adherence was monitored using an electronic system. Results were discussed with the patients in motivational interviews, and drug prescription adapted accordingly. In the UC group, drug adherence was monitored, but results were not available. Results. At six months, 84% of patients in the IC group achieved recommended iPTH targets versus 55% in the UC group (P = 0.04). The mean cinacalcet taking adherence improved by 10.8% in the IC group and declined by 5.3% in the UC group (P = 0.02). Concomitantly, the mean dose of cinacalcet was reduced by 7.2 mg/day in the IC group and increased by 6.4 mg/day in the UC group (P = 0.03). Conclusions. The use of a drug adherence monitoring program in the management of sHPT in hemodialysis patients receiving cinacalcet improves drug adherence and iPTH control and allows a reduction in the dose of cinacalcet.

[1]  F. Locatelli,et al.  Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.

[2]  F. Paccaud,et al.  Monitoring one-year compliance to antihypertension medication in the Seychelles. , 2002, Bulletin of the World Health Organization.

[3]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[4]  R B Haynes,et al.  Predicting compliance with a regimen of digoxin therapy in family practice. , 1980, Canadian Medical Association journal.

[5]  A. Paes,et al.  Impact of Dosage Frequency on Patient Compliance , 1997, Diabetes Care.

[6]  Mahmoud Loghman-Adham,et al.  Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. , 2003, The American journal of managed care.

[7]  B. Svarstad,et al.  Hemodialysis patients' noncompliance with oral medications. , 1999, ANNA journal.

[8]  W. Goodman,et al.  Association of cinacalcet adherence and costs in patients on dialysis , 2011, Journal of medical economics.

[9]  E. Lesaffre,et al.  Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once‐daily atorvastatin , 2006, Pharmacoepidemiology and drug safety.

[10]  W. Goodman,et al.  The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. , 2002, Journal of the American Society of Nephrology : JASN.

[11]  S. Fukuhara,et al.  Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. , 2003, Kidney international.

[12]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[14]  M. Burnier,et al.  Monitoring compliance in resistant hypertension: an important step in patient management. , 2003, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[15]  S. Ganesh,et al.  Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.

[16]  J. Leggat.  PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Adherence with Dialysis: A Focus on Mortality Risk , 2005 .

[17]  F. Port,et al.  Noncompliance in hemodialysis: predictors and survival analysis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  B. Culleton,et al.  Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  John Urquhart,et al.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.